AbbVie (NYSE: ABBV) announced today global resolution of all intellectual property-related litigation with Samsung Bioepis over its proposed biosimilar adalimumab ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE